$4.96
Value $431M
SRTA and UNP stock compared: price, dividend, valuation and results, from SEC filings.
$4.96
Value $431M
$300.90
Value $179B
Strata Critical Medical (SRTA) has a market value of $431M and Union Pacific (UNP) $179B. Over the last year, with dividends, SRTA moved +11.5% and UNP +39.0%. Dividend yield: SRTA none, UNP 1.85%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
SRTA$431M
UNP$179B
UNP is 414 times SRTA
Revenue, 12 months
SRTA$281M
UNP$26.4B
UNP is 94 times SRTA
Net income, 12 months
SRTA-$25M
UNP$7.6B
Operating margin
SRTA-6.6%
UNP40.1%
46.7 points apart
ROIC
SRTA-5.2%
UNP16.1%
21.3 points apart
P/E
SRTA–
UNP23.4
Dividend yield
SRTA0.0%
UNP1.8%
1.9 points apart
5-year return
SRTA-52.3%
UNP+40.3%
92.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
SRTA-52.3%
UNP+40.3%
| Period | SRTAWith dividends | UNPWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +11.5%Price +11.5% | +39.0%Price +36.2% |
| 3 years since November 17, 2023 | +38.5%+11.5% a yearPrice +38.5% | +46.6%+13.6% a yearPrice +37.3% |
| 5 years since November 17, 2021 | -52.3%-13.7% a yearPrice -52.3% | +40.3%+7.0% a yearPrice +25.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
SRTAStrata Critical MedicalUNPUnion Pacific
| Price | $4.96 | $300.90 |
|---|---|---|
| Market value | $431M | $179B |
| Enterprise value (EV) | $390M | $207B |
| P/E | – | 23.4 |
| P/E, 5-year median | – | 20.6 |
| P/B | 1.6 | 8.1 |
| EV/EBIT | – | 19.6 |
| Free cash flow yield | 0.2% | 3.8% |
| Revenue, 12 months | $281M | $26.4B |
|---|---|---|
| Net income, 12 months | -$25M | $7.6B |
| Free cash flow, 12 months | $806.0K | $6.7B |
| Earnings per share, 12 months | -$0.30 | $12.83 |
| Revenue growth, year on year | 34.3% | 1.1% |
| Revenue growth a year, past | +53.1%over 5 years | +4.6%over 5 years |
| EPS growth a year, past | – | +8.7%over 5 years |
| Gross margin | 21.6% | – |
|---|---|---|
| Operating margin | -6.6% | 40.1% |
| Net margin | -8.8% | 28.9% |
| ROIC | -5.2% | 16.1% |
| ROE | -8.8% | 38.9% |
| Cash | $42M | $2.2B |
|---|---|---|
| Total debt | $3.6M | $31.1B |
| Net debt / EBITDA | – | 2.2 |
| Interest cover | – | 8.3× |
| Dividend yield | – | 1.8% |
|---|---|---|
| Dividend per share, 12 months | – | $5.56 |
| Dividend growth a year, past | – | +7.0%over 5 years |
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 3.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Union Pacific ($179B) is about 413.8 times Strata Critical Medical ($431M), at today's prices.
Since November 17, 2021, SRTA's price moved -52.3% and UNP's +25.5%. With dividends: SRTA -52.3% (-13.7% a year), UNP +40.3% (+7.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Strata Critical Medical and 1.85% for Union Pacific. Over the last twelve months they paid – and $5.56 per share.
Over the last twelve months, the net margin was -8.8% for Strata Critical Medical and 28.9% for Union Pacific, and the operating margin -6.6% and 40.1%. Revenue was $281M and $26.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.